Santa-Maria CA, et al. - In the Zoledronic Acid Prophylaxis (ZAP) trial, researchers investigated if bisphosphonates are related to reduced incidence of aromatase inhibitor-associated musculoskeletal symptoms (AIMSS). From the Exemestane and Letrozole Pharmacogenomics (ELPh) trial, historical controls were included and compared in terms of the incidence of AIMSS with postmenopausal women with stage 0-III breast cancer planning to take adjuvant AIs. Prior to initiating letrozole and after 6 months, zoledronic acid was given to the participants in the ZAP trial; ELPh participants included in the analysis were taking letrozole but not bisphosphonates. They found that administration of zoledronic acid concomitantly with adjuvant AIs was related to a reduced incidence of AIMSS, compared with historical controls.